AI-generated from publicly available materials.Orange has made a strategic investment in French health-tech startup Biolevate, aiming to enhance its presence in the life sciences sector and foster innovation within the French technology landscape.
This funding, facilitated through Orange Ventures, is part of Biolevate's second financing round and positions the company favorably within the French tech ecosystem. Biolevate has been recognized in the 2025 French Tech 2030 program, which promotes technologies deemed crucial for France's technological sovereignty. The company's focus on knowledge-driven automation aims to expedite the transition from drug discovery to patient access, utilizing an AI platform that streamlines various healthcare innovation processes.
Biolevate's technology reportedly accelerates pharmaceutical processes by up to 50%, significantly reducing the time it takes for potentially life-saving treatments to reach patients. This aligns with Orange's broader strategy of integrating digital technologies into healthcare, as the company collaborates with Biolevate and its affiliate, Enovalife, to enhance operational workflows in the pharmaceutical sector.
The partnership aims to transform AI from a mere experimental tool into a practical solution for the complex regulatory and operational challenges faced by pharmaceutical organizations. This investment not only strengthens Orange's foothold in the healthcare sector but also positions the company as a key player in integrating trusted AI into critical health infrastructure, ultimately supporting the responsible and secure use of AI in pharmaceutical R&D.